These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 3363755)

  • 1. Effects of transcutaneous scopolamine and depth on diver performance.
    Williams TH; Wilkinson AR; Davis FM; Frampton CM
    Undersea Biomed Res; 1988 Mar; 15(2):89-98. PubMed ID: 3363755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of double-dose transdermal scopolamine.
    Bar R; Gil A; Tal D
    Pharmacotherapy; 2009 Sep; 29(9):1082-8. PubMed ID: 19698013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three-years' experience of transdermal scopolamine: long-term effectiveness and side-effects.
    Shupak A; Gordon CR; Spitzer O; Mendelowitz N; Melamed Y
    Pharmatherapeutica; 1989; 5(6):365-70. PubMed ID: 2594820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transdermal scopolamine: a review of its effects upon motion sickness, psychological performance, and physiological functioning.
    Parrott AC
    Aviat Space Environ Med; 1989 Jan; 60(1):1-9. PubMed ID: 2647072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of transdermal scopolamine against seasickness: a 3-day study at sea.
    Attias J; Gordon C; Ribak J; Binah O; Rolnick A
    Aviat Space Environ Med; 1987 Jan; 58(1):60-2. PubMed ID: 3814034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transdermal scopolamine in the prevention of motion sickness: evaluation of the time course of efficacy.
    Homick JL; Kohl RL; Reschke MF; Degioanni J; Cintron-Trevino NM
    Aviat Space Environ Med; 1983 Nov; 54(11):994-1000. PubMed ID: 6651736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of antimotion sickness drug side effects on performance.
    Wood CD; Manno JE; Manno BR; Redetzki HM; Wood MJ; Mims ME
    Aviat Space Environ Med; 1985 Apr; 56(4):310-6. PubMed ID: 3888169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scopolamine bioavailability in combined oral and transdermal delivery.
    Nachum Z; Shahal B; Shupak A; Spitzer O; Gonen A; Beiran I; Lavon H; Eynan M; Dachir S; Levy A
    J Pharmacol Exp Ther; 2001 Jan; 296(1):121-3. PubMed ID: 11123371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transdermal scopolamine: human performance and side effects.
    Gordon C; Binah O; Attias J; Rolnick A
    Aviat Space Environ Med; 1986 Mar; 57(3):236-40. PubMed ID: 3964152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Side effects of antimotion sickness drugs.
    Wood CD; Manno JE; Manno BR; Redetzki HM; Wood M; Vekovius WA
    Aviat Space Environ Med; 1984 Feb; 55(2):113-6. PubMed ID: 6696702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects of scopolamine and amphetamine on microcomputer-based performance tests.
    Kennedy RS; Odenheimer RC; Baltzley DR; Dunlap WP; Wood CD
    Aviat Space Environ Med; 1990 Jul; 61(7):615-21. PubMed ID: 2386447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of transdermal scopolamine upon psychological test performance at sea.
    Parrott AC; Jones R
    Eur J Clin Pharmacol; 1985; 28(4):419-23. PubMed ID: 4029247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transdermal scopolamine for prevention of intrathecal morphine-induced nausea and vomiting after cesarean delivery.
    Harnett MJ; O'Rourke N; Walsh M; Carabuena JM; Segal S
    Anesth Analg; 2007 Sep; 105(3):764-9. PubMed ID: 17717237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental motion sickness: efficacy of transdermal scopolamine plus ephedrine.
    Graybiel A; Cramer DB; Wood CD
    Aviat Space Environ Med; 1981 Jun; 52(6):337-9. PubMed ID: 7259691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of scopolamine and dextroamphetamine on human performance.
    Schmedtje JF; Oman CM; Letz R; Baker EL
    Aviat Space Environ Med; 1988 May; 59(5):407-10. PubMed ID: 3390096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Visual reaction time performance preceding CNS oxygen toxicity.
    Curley MD; Butler FK
    Undersea Biomed Res; 1987 Jul; 14(4):301-10. PubMed ID: 3629742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of dimenhydrinate, cinnarizine and transdermal scopolamine on performance.
    Gordon CR; Gonen A; Nachum Z; Doweck I; Spitzer O; Shupak A
    J Psychopharmacol; 2001 Sep; 15(3):167-72. PubMed ID: 11565623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychometric evaluation of divers performing a series of heliox non-saturation dives.
    Hodgson M; Golding JF
    Aviat Space Environ Med; 1991 May; 62(5):407-13. PubMed ID: 2053904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of effect sizes to characterize the nature of cognitive change in psychopharmacological studies: an example with scopolamine.
    Fredrickson A; Snyder PJ; Cromer J; Thomas E; Lewis M; Maruff P
    Hum Psychopharmacol; 2008 Jul; 23(5):425-36. PubMed ID: 18421801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Change in strategy of solving psychological tests: evidence of nitrogen narcosis in shallow air-diving.
    Petri NM
    Undersea Hyperb Med; 2003; 30(4):293-303. PubMed ID: 14756232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.